Clinical Trial Update: A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

View source ↗

Summary

A post-marketing surveillance study to assess the safety of fedratinib in Korean patients with myelofibrosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Status: RECRUITING